Literature DB >> 24849621

Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

A M Young1, R J DiClemente, D S Halgin, C E Sterk, J R Havens.   

Abstract

This study examined feasibility of peer-based promotion of HIV vaccination and dyadic correlates to vaccine encouragement in risk- and non-risk networks of drug users (n = 433) in the US. Data were collected on HIV vaccine attitudes, risk compensation intentions, likelihood of encouraging vaccination, and recent (past 6 months) risk (i.e. involving sex and/or injecting drugs) and non-risk (i.e. involving co-usage of noninjected drugs and/or social support) relationships. Willingness to encourage HIV vaccination was reported in 521 and 555 risk- and non-risk relationships, respectively. However, 37 % expressed hesitancy, typically due to fear of side effects or social concerns. Encouragement was often motivated by perceived HIV risk, though 9 % were motivated by risk compensation intentions. In non-risk partnerships, encouragement was associated with drug co-usage, and in risk relationships, with perceived vaccine acceptability and encouragement by the partner. Network-based HIV vaccine promotion may be a successful strategy, but risk compensation intentions should be explored.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24849621      PMCID: PMC4279243          DOI: 10.1007/s10461-014-0797-9

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  37 in total

1.  Sociometric risk networks and risk for HIV infection.

Authors:  S R Friedman; A Neaigus; B Jose; R Curtis; M Goldstein; G Ildefonso; R B Rothenberg; D C Des Jarlais
Journal:  Am J Public Health       Date:  1997-08       Impact factor: 9.308

2.  Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa.

Authors:  Graham Lindegger; Michael Quayle; Moses Ndlovu
Journal:  Health Educ Behav       Date:  2006-05-31

3.  Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis.

Authors:  April M Young; Jennifer R Havens
Journal:  Addiction       Date:  2011-10-26       Impact factor: 6.526

4.  Socioecological influences on community involvement in HIV vaccine research.

Authors:  Paula M Frew; Matthew Archibald; Brooke Hixson; Carlos del Rio
Journal:  Vaccine       Date:  2011-06-29       Impact factor: 3.641

5.  Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States.

Authors:  Mary A Allen; Thomas S Liang; Thomas La Salvia; Brian Tjugum; Robert J Gulakowski; Matthew Murguía
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

6.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

7.  "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown.

Authors:  Peter A Newman; Carmen Logie; Llana James; Tamicka Charles; John Maxwell; Khaled Salam; Michael Woodford
Journal:  Am J Public Health       Date:  2011-07-21       Impact factor: 9.308

8.  Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter?

Authors:  Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Jennifer R Havens; April Young
Journal:  Ann Epidemiol       Date:  2012-08-14       Impact factor: 3.797

9.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

10.  Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

Authors:  Maria Goretti P Fonseca; Steven Forsythe; Alexandre Menezes; Shilpa Vuthoori; Cristina Possas; Valdiléa Gonçalves Veloso; Valdiléa Veloso; Francisca de Fátima Lucena; John Stover
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

View more
  6 in total

Review 1.  Quality of Care and Service Expansion for HIV Care and Treatment.

Authors:  Carolyn Bolton Moore; Erica Ciaraldi
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

2.  Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination.

Authors:  April M Young; Daniel S Halgin; Jennifer R Havens
Journal:  AIDS Care       Date:  2015-03-02

3.  Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment.

Authors:  April M Young; Dustin B Stephens; Hanan A Khaleel; Jennifer R Havens
Journal:  Contemp Clin Trials       Date:  2014-12-30       Impact factor: 2.226

Review 4.  Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned.

Authors:  April M Young; Abby E Rudolph; Jennifer R Havens
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

Review 5.  Attitudes Toward the Ethics of Research Using Social Media: A Systematic Review.

Authors:  Su Golder; Shahd Ahmed; Gill Norman; Andrew Booth
Journal:  J Med Internet Res       Date:  2017-06-06       Impact factor: 5.428

6.  HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study.

Authors:  April M Young; Ralph J DiClemente; Daniel S Halgin; Claire E Sterk; Jennifer R Havens
Journal:  BMC Public Health       Date:  2014-05-30       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.